Browsing by Author "Ming Ta Michael Lee"

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    PublicationMetadata only
    Research Directions in Genetic Predispositions to Stevens–Johnson Syndrome / Toxic Epidermal Necrolysis
    (2018-03-01) Teri A. Manolio; Carolyn M. Hutter; Mark Avigan; Ricardo Cibotti; Robert L. Davis; Joshua C. Denny; Lois La Grenade; Lisa M. Wheatley; Mary N. Carrington; Wasun Chantratita; Wen Hung Chung; Andrea D. Dalton; Shuen Iu Hung; Ming Ta Michael Lee; J. Steven Leeder; Juan J.L. Lertora; Surakameth Mahasirimongkol; Howard L. McLeod; Maja Mockenhaupt; Michael Pacanowski; Elizabeth J. Phillips; Simone Pinheiro; Munir Pirmohamed; Cynthia Sung; Wimon Suwankesawong; Lauren Trepanier; Santa J. Tumminia; David Veenstra; Rika Yuliwulandari; Neil H. Shear; Leidos Inc.; National Yang-Ming University Taiwan; Chang Gung Memorial Hospital; Universität Freiburg im Breisgau; University of Wisconsin Madison, School of Veterinary Medicine; Massachusetts Institute of Technology; The Food and Drug Administration, Thailand Ministry of Public Health; University of Liverpool; Chang Gung University; Murdoch University; Children's Mercy Hospitals and Clinics; National Institute of Allergy and Infectious Diseases; National University of Singapore; University of Toronto; NIH Clinical Center; Faculty of Medicine, Ramathibodi Hospital, Mahidol University; Thailand Ministry of Public Health; University of Washington, Seattle; National Human Genome Research Institute; Food and Drug Administration; Geisinger Health System; National Eye Institute; National Institute of Arthritis and Musculoskeletal and Skin Diseases; Moffitt Cancer Center; Vanderbilt University; University of Tennessee Health Science Center; Stevens-Johnson Syndrome Foundation; YARSI University
    © 2017 American Society for Clinical Pharmacology and Therapeutics Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is one of the most devastating of adverse drug reactions (ADRs) and was, until recently, essentially unpredictable. With the discovery of several risk alleles for drug-induced SJS/TEN and the demonstration of effectiveness of screening in reducing incidence, the stage is set for implementation of preventive strategies in populations at risk. Yet much remains to be learned about this potentially fatal complication of commonly used drugs.
  • No Thumbnail Available
    PublicationMetadata only
    Success stories in genomic medicine from resource-limited countries
    (2015-01-01) Konstantinos Mitropoulos; Hayat Al Jaibeji; Diego A. Forero; Paul Laissue; Ambroise Wonkam; Catalina Lopez-Correa; Zahurin Mohamed; Wasun Chantratita; Ming Ta Michael Lee; Adrian Llerena; Angela Brand; Bassam R. Ali; George P. Patrinos; The Golden Helix Foundation; Maastricht University; College of Medicine and Health Sciences United Arab Emirates University; Universidad Antonio Nariño; Universidad del Rosario; University of Cape Town, Faculty of Health Sciences; Genome Quebec; University of Malaya; Mahidol University; Riken; Academia Sinica, Institute of Biomedical Sciences; Universidad de Extremadura; Panepistimion Patron
    © 2015 Mitropoulos et al. In recent years, the translation of genomic discoveries into mainstream medical practice and public health has gained momentum, facilitated by the advent of new technologies. However, there are often major discrepancies in the pace of implementation of genomic medicine between developed and developing/resource-limited countries. The main reason does not only lie in the limitation of resources but also in the slow pace of adoption of the new findings and the poor understanding of the potential that this new discipline offers to rationalize medical diagnosis and treatment. Here, we present and critically discuss examples from the successful implementation of genomic medicine in resource-limited countries, focusing on pharmacogenomics, genome informatics, and public health genomics, emphasizing in the latter case genomic education, stakeholder analysis, and economics in pharmacogenomics. These examples can be considered as model cases and be readily replicated for the wide implementation of pharmacogenomics and genomic medicine in other resource-limited environments.